New target for Oncoceutics' GPCR-targeting compounds
Oncoceutics' compounds increase mitochondrial protease activity to kill cancer
Two academic teams have discovered Oncoceutics’ GPCR-targeting products kill cancer via an alternative mechanism: triggering apoptosis by activating a mitochondrial protease.
Oncoceutics Inc. is developing a pipeline of imipridones to antagonize or agonize GPCRs including dopamine receptors. Oncoceutics’ management team told BioCentury its lead product, ONC201, directly antagonizes DRD2 and a related dopamine receptor to inhibit oncogenic signaling pathways in multiple cancer types. ONC201 is in over 10 clinical trials for indications including triple-negative breast cancer (TNBC), glioma and leukemia...